ACCEL | Terminology is evolving but, whatever you call them, anticoagulant agents that are alternatives to warfarin are taking a firm hold in the United States. In a soon-to-be-published paper tracking the initiation patterns of 6,893 patients prescribed an anticoagulant from 2010 through 2013, Desai et al. found that 62% of new anticoagulant prescriptions were for one of the newer agents: dabigatran, rivaroxaban, or apixaban.¹ (A fourth, edoxaban, is working its w...